2-氧代环己烷甲腈 | 58706-66-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氧代环己烷甲腈
• 英文名称: 3-[acetyI(methyl)amino]propanoic acid
• 英文别名: 3-[acetyl(methyl)amino]propanoic acid
• CAS: 58706-66-4
• 化学式: C₆H₁₁NO₃
• 分子量: 145.158
• InChiKey: CUAUMKXJKVIJHG-UHFFFAOYSA-N

物化性质

• 熔点：
  91～92℃
• 沸点：
  150/15mm
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  2-氧代环己烷甲腈 在 sodium hydroxide 、 sodium methylate 、 N,N'-羰基二咪唑 、 magnesium chloride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 5-[2-(Acetyl-methyl-amino)-ethyl]-3-(2,6-dichloro-phenyl)-isoxazole-4-carboxylic acid
  参考文献：
  名称：

  Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists

  摘要：

  Novel isoxazole carboxamides have been identified as growth hormone secretagogue receptor (GHS-R) antagonists. Substituent modification off the 5-position of the isoxazole ring led to analogues with potent binding affinity and functional antagonism of GHS-R. A potent analogue (32) with high aqueous solubility and good GPCR selectivity was also identified as a potential pharmacological tool for in vivo studies. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.060

文献信息

• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
• [EN] CRF RECEPTOR ANTAGONISTS AND METHODS OF USE<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CRF ET MÉTHODES D'UTILISATION
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2021062246A1

  公开（公告）日：2021-04-01

  Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).

  本文提供了化合物，以及相关的制剂、组合物和治疗方法，用于治疗需要这些治疗的疾病和/或疾病，例如先天性肾上腺皮质增生症（CAH）。
• Per-Residue Program of Multiple Backbone Dihedral Angles of β-Peptoids via Backbone Substitutions
  作者：Jumpei Morimoto、Jungyeon Kim、Daisuke Kuroda、Satoru Nagatoishi、Kouhei Tsumoto、Shinsuke Sando

  DOI：10.1021/jacs.9b10496

  日期：2020.2.5

  report a strategy for per-residue programming of two dihedral angles of β-peptoids, which is useful for restricting conformational space of the oligomers. The oligomer was found to form a unique loop conformation that is stabilized by the backbone rotational restrictions. Circular dichroism and NMR spectroscopic analyses and X-ray crystallographic analysis of the oligomer are presented. The strategy would

  天然和合成低聚物的独特折叠结构是其独特功能的最基本基础。N-取代的 β-肽或 β-类肽是合成低聚物，具有折叠成不同三维结构的巨大潜力，因为单体中存在四个可旋转的键，并且具有高度模块化的合成可访问性。然而，四个可旋转键的存在对β-拟肽的构象控制提出了挑战。在这里，我们报告了 β-peptoids 的两个二面角的每个残基编程的策略，这对于限制寡聚体的构象空间很有用。发现低聚物形成独特的环构象，该构象通过骨架旋转限制而稳定。给出了低聚物的圆二色性和 NMR 光谱分析和 X 射线晶体学分析。该策略将显着促进发现许多更独特的 β-拟肽折叠结构。
• Disubstituted Aniline Compounds
  申请人：Heidebrecht Richard

  公开号：US20090221669A1

  公开（公告）日：2009-09-03

  The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit hi-stone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的二取代苯胺化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于选择性诱导终末分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫、过敏和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，例如神经退行性疾病。本发明还提供了包含本发明的化合物的制药组合物和这些制药组合物的安全用量方案，这些方案易于遵循，并在体内产生治疗有效量的这些化合物。
• PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
  申请人：Lynch Rosemary

  公开号：US20120065202A1

  公开（公告）日：2012-03-15

  The invention relates to compounds of formula (I) wherein X, R 1 , R 2 , T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及式(I)的化合物，其中X，R1，R2，T，m，n，o的含义如所述和权利要求所述。所述化合物可用作mTOR的抑制剂，用于治疗或预防mTOR相关疾病和疾病。本发明还涉及包括所述化合物的制药组合物，以及作为药物的使用和制备这些化合物。

表征谱图